[Alizapride versus placebo in premedication for esophagogastroduodenoscopy. Double-blind clinical study. Experimental research in vitro].

The pronounced antiemetic properties of Alizapride, one of the new azimidobenzamides suggested the assessment of its efficacy on 40 patients due for oesophagogastroduodenoscopy. The drug proved highly satisfactory as premedication for the examination, significantly inhibiting vomiting and stomach wall tone during the examination as was indicated by in vitro studies.
AuthorsF Cosentino, A Prato, A Laudani, S Percolla, S Franco, P F Veroux, A Immè
JournalMinerva dietologica e gastroenterologica (Minerva Dietol Gastroenterol) 1989 Jan-Mar Vol. 35 Issue 1 Pg. 35-7 ISSN: 0391-1993 [Print] ITALY
Vernacular TitleAlizapride vs. placebo nella premedicazione all'esofagogastroduodenoscopia. Studio clinico in doppio cieco. Ricerche sperimentali in vitro.
PMID2725928 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Antiemetics
  • Pyrrolidines
  • alizapride
  • Animals
  • Antiemetics (pharmacology, therapeutic use)
  • Double-Blind Method
  • Duodenoscopy (adverse effects)
  • Endoscopy (adverse effects)
  • Esophagoscopy (adverse effects)
  • Gastrointestinal Motility (drug effects)
  • Gastroscopy (adverse effects)
  • Humans
  • In Vitro Techniques
  • Premedication
  • Pyrrolidines (pharmacology, therapeutic use)
  • Random Allocation
  • Rats
  • Vomiting (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: